Sort   by:  
 Page size 
ProteomicsLymphodepleting chemotherapy potentiates neoantigen-directed T-cell therapy by enhancing antigen presentation
Adoptive cell therapy (ACT) targeting tumor-specific antigens holds promise for solid-tumors, but limited neoantigen presentation remains a key barrier to efficacy. Here, we identify and characterize a T-cell receptor (TCR), T104, for the KRAS.G12V mutation, a prevalent neoantigen in colorectal, lun...
ORGANISM(S): Homo sapiens (Human) 
2026-01-12 | PXD070607 | Pride
Kras g12v Lymphodepleting chemotherapy Proteomics Kras g12c Tcr therapy Neoantigens Colon cancer. Adoptive cell therapy Immunotheraphy Pancreatic cancer 
ProteomicsTCR targeting of KRAS G12V/C neoantigens is enhanced by lymphodepleting chemotherapy
Lung cancer remains the leading cause of cancer-related deaths worldwide. Immunotherapy agents have doubled treatment response rates in non-small cell lung cancer (NSCLC). However, these responses are neither universal nor consistently durable, underscoring the need for innovative therapeutic strate...
ORGANISM(S): Homo sapiens (Human) 
2025-10-03 | PXD061178 | Pride
Lymphodepleting chemotherapy Lung cancer Kras g12v Kras g12c Tcr therapy Neoantigens Colon cancer. Adoptive cell therapy Pancreatic cancer 
Sort   by:  
 Page size